美国胃肠病学会临床实践更新:高危个体胰腺癌筛查专家综述
美国胃肠病学会学院临床实践更新基于高危个体胰腺癌筛查研究报道与专家意见,提出13条最佳实践建议,涵盖筛查适用人群、遗传咨询、起始年龄、筛查方式、随访间隔及多学科决策等,旨在规范高危个体胰腺癌筛查。
要点
- 高危个体应接受胰腺癌筛查,包括胰腺癌患者的一级亲属中至少2名遗传相关亲属患病者。
- 推荐磁共振成像联合内镜超声作为首选筛查方式,起始年龄50岁或比家族最早发病年龄提前10年。
- 平均风险个体不应筛查;筛查局限性与潜在风险应在启动筛查前与患者讨论。
核心结论
- 美国胃肠病学会学院临床实践更新提出13条最佳实践建议,规范高危个体胰腺癌筛查的适用人群、遗传咨询、起始年龄、筛查方式、随访间隔及多学科决策。
研究设计与样本
- 美国胃肠病学会学院临床实践更新,证据基于高危个体胰腺癌筛查研究报道与专家意见。
主要发现
- 高危个体包括胰腺癌患者的一级亲属中至少2名遗传相关亲属患病者。
- 遗传综合征相关高危个体包括所有Peutz-Jeghers综合征患者、遗传性胰腺炎患者、CDKN2A基因突变患者,以及Lynch综合征伴1名或以上一级亲属患胰腺癌者、BRCA1、BRCA2、PALB2和ATM基因突变者。
- 筛查起始年龄为50岁,或比家族最早发病年龄提前10年;CDKN2A和PRSS1突变携带者伴遗传性胰腺炎者起始年龄40岁,Peutz-Jeghers综合征起始年龄35岁。
- 首选筛查方式为磁共振成像联合内镜超声。
- 筛查目标可检出肿瘤为可切除I期胰腺导管腺癌及高危前驱肿瘤,如伴高级别异型增生的导管内乳头状黏液性肿瘤和部分增大的胰腺上皮内瘤变。
关键数值与推荐
- 最佳实践建议1:胰腺癌筛查应考虑用于确定的高危患者,包括胰腺癌患者的一级亲属中至少2名遗传相关亲属患病者。
- 最佳实践建议2:胰腺癌筛查应考虑用于遗传综合征相关风险增高患者,包括所有Peutz-Jeghers综合征、遗传性胰腺炎、CDKN2A基因突变患者,以及Lynch综合征伴1名或以上一级亲属患胰腺癌者和BRCA1、BRCA2、PALB2、ATM基因突变者。
- 最佳实践建议3:对符合监测条件的家族性胰腺癌亲属,应考虑遗传检测和咨询。
- 最佳实践建议4:高危患者进行胰腺癌筛查时,应尽可能参与登记或转诊至胰腺卓越中心。
- 最佳实践建议5:临床医生不应筛查平均风险个体。
临床怎么用
- 高危个体应接受胰腺癌筛查,平均风险个体不应筛查。
- 筛查首选磁共振成像联合内镜超声,起始年龄50岁或比家族最早发病年龄提前10年。
- 遗传检测和咨询应考虑用于符合监测条件的家族性胰腺癌亲属。
- 筛查决策和治疗应由多学科团队与患者及家属共同制定,手术切除应在高容量中心进行。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: The purpose of this American Gastroenterological Association Institute Clinical Practice Update is to describe the indications for screening for pancreas cancer in high-risk individuals. METHODS: The evidence reviewed in this work is based on reports of pancreas cancer screening studies in high-risk individuals and expert opinion. BEST PRACTICE ADVICE 1: Pancreas cancer screening should be considered in patients determined to be at high risk, including first-degree relatives of patients with pancreas cancer with at least 2 affected genetically related relatives. BEST PRACTICE ADVICE 2: Pancreas cancer screening should be considered in patients with genetic syndromes associated with an increased risk of pancreas cancer, including all patients with Peutz-Jeghers syndrome, hereditary pancreatitis, patients with CDKN2A gene mutation, and patients with 1 or more first-degree relatives with pancreas cancer with Lynch syndrome, and mutations in BRCA1, BRCA2, PALB2, and ATM genes. BEST PRACTICE ADVICE 3: Genetic testing and counseling should be considered for familial pancreas cancer relatives who are eligible for surveillance. A positive germline mutation is associated with an increased risk of neoplastic progression and may also lead to screening for other relevant associated cancers. BEST PRACTICE ADVICE 4: Participation in a registry or referral to a pancreas Center of Excellence should be pursued when possible for high-risk patients undergoing pancreas cancer screening. BEST PRACTICE ADVICE 5: Clinicians should not screen average-risk individuals for pancreas cancer. BEST PRACTICE ADVICE 6: Pancreas cancer screening in high-risk individuals should begin at age 50 years, or 10 years younger than the initial age of familial onset. Screening should be initiated at age 40 years in CKDN2A and PRSS1 mutation carriers with hereditary pancreatitis and at age 35 years in the setting of Peutz-Jeghers syndrome. BEST PRACTICE ADVICE 7: Magnetic resonance imaging and endoscopic ultrasonography (EUS) should be used in combination as the preferred screening modalities in individuals undergoing pancreas cancer screening. BEST PRACTICE ADVICE 8: The target detectable pancreatic neoplasms are resectable stage I pancreatic ductal adenocarcinoma and high-risk precursor neoplasms, such as intraductal papillary mucinous neoplasms with high-grade dysplasia and some enlarged pancreatic intraepithelial neoplasias. BEST PRACTICE ADVICE 9: Screening intervals of 12 months should be considered when there are no concerning pancreas lesions, with shortened intervals and/or the performance of EUS in 6-12 months directed towards lesions determined to be low risk (by a multidisciplinary team). EUS evaluation should be performed within 3-6 months for indeterminate lesions and within 3 months for high-risk lesions, if surgical resection is not planned. New-onset diabetes in a high-risk individual should lead to additional diagnostic studies or change in surveillance interval. BEST PRACTICE ADVICE 10: Decisions regarding therapy directed towards abnormal findings detected during screening should be made by a dedicated multidisciplinary team together with the high-risk individual and their family. BEST PRACTICE ADVICE 11: Surgical resection should be performed at high-volume centers. BEST PRACTICE ADVICE 12: Clinicians should consider discontinuing pancreas cancer screening in high-risk individuals when they are more likely to die of non-pancreas cancer-related causes due to comorbidity and/or are not candidates for pancreas resection. BEST PRACTICE ADVICE 13: The limitations and potential risks of pancreas cancer screening should be discussed with patients before initiating a screening program.
引用
- Aslanian HR, Lee JH, Canto MI, et al. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review. Gastroenterology. 2020. PMID: 32416142. doi:10.1053/j.gastro.2020.03.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。